Genmab A/S (OTCMKTS:GNMSF) Posts Earnings Results, Beats Expectations By $1.86 EPS

Genmab A/S (OTCMKTS:GNMSF) issued its earnings results on Thursday. The company reported $5.42 EPS for the quarter, topping analysts’ consensus estimates of $3.56 by $1.86, Zacks reports. Genmab A/S had a net margin of 21.05% and a return on equity of 15.34%.

Genmab A/S Stock Up 1.7%

OTCMKTS:GNMSF traded up $5.00 during mid-day trading on Thursday, reaching $295.00. The company’s stock had a trading volume of 248 shares, compared to its average volume of 1,912. The company has a quick ratio of 2.17, a current ratio of 2.18 and a debt-to-equity ratio of 0.87. The stock has a fifty day moving average of $268.22 and a 200-day moving average of $279.28. Genmab A/S has a 1 year low of $232.30 and a 1 year high of $352.00. The firm has a market capitalization of $18.16 billion, a PE ratio of 22.25 and a beta of 0.77.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.